Page last updated: 2024-09-05

lenalidomide and amg531

lenalidomide has been researched along with amg531 in 7 studies

Compound Research Comparison

Studies
(lenalidomide)
Trials
(lenalidomide)
Recent Studies (post-2010)
(lenalidomide)
Studies
(amg531)
Trials
(amg531)
Recent Studies (post-2010) (amg531)
3,5327252,85071394607

Protein Interaction Comparison

ProteinTaxonomylenalidomide (IC50)amg531 (IC50)
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 28.27
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.6605
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)3.1

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A1
Sekeres, MA1
Carraway, HE; Gore, SD; Loaiza-Bonilla, A1
Bhagat, T; Braunschweig, I; Roth, M; Schinke, C; Steidl, U; Tamari, R; Verma, A; Will, B1
Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N1
Patel, BJ; Sekeres, MA1
Berdeja, J; Bhagat, P; Braunschweig, I; Donnellan, WB; Fehn, K; Goldfinger, M; Gonzalez-Lugo, JD; Gritsman, K; Jasra, S; Kambhampati, S; Kazemi, M; Kim, M; Kornblum, N; Mantzaris, I; Pradhan, K; Remy, C; Shah, N; Shastri, A; Sica, RA; Steidl, U; Verma, A; Will, B; Yacoub, A1

Reviews

5 review(s) available for lenalidomide and amg531

ArticleYear
[Novel medical treatment modalities in hematology].
    Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24

    Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine

2008
Treatment of MDS: something old, something new, something borrowed...
    Hematology. American Society of Hematology. Education Program, 2009

    Topics: Azacitidine; Benzoates; Blood Transfusion; Bone Marrow Diseases; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA-Cytosine Methylases; Glutathione; Hematinics; Humans; Hydrazines; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Risk; Thalidomide; Thrombopoietin

2009
Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents.
    Current opinion in hematology, 2010, Volume: 17, Issue:2

    Topics: Antineoplastic Agents; Benzoates; Enzyme Inhibitors; Humans; Hydrazines; Lenalidomide; Methyltransferases; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Thalidomide; Treatment Outcome

2010
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    The Cochrane database of systematic reviews, 2017, 09-30, Volume: 9

    Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin

2017
Lowering the boom on lower-risk myelodysplastic syndromes.
    Hematology. American Society of Hematology. Education Program, 2019, 12-06, Volume: 2019, Issue:1

    Topics: Activin Receptors, Type II; Aged; Antilymphocyte Serum; Benzoates; Bone Marrow Cells; Female; Hematinics; Humans; Hydrazines; Immunoglobulin Fc Fragments; Lenalidomide; Mutation; Myelodysplastic Syndromes; Pyrazoles; Recombinant Fusion Proteins; Risk Factors; Thrombocytopenia

2019

Trials

1 trial(s) available for lenalidomide and amg531

ArticleYear
Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 01-04, Volume: 29, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Benzoates; Hemorrhage; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Thrombocytopenia; Treatment Outcome

2023

Other Studies

1 other study(ies) available for lenalidomide and amg531

ArticleYear
Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Benzoates; Cell Line, Tumor; Cell Proliferation; Clonal Evolution; Female; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Megakaryocyte Progenitor Cells; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Thalidomide; Thrombopoiesis

2014